SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
LONA reported quarter ended September 30, 2026 results. The price and volatility reaction is pending.
LONAearnings

Earnings reactions, page 2

LeonaBio, Inc. (LONA) FY2026 earnings

November 17, 2026 · SharpeIQ Research Desk

Reported results

  • Net loss was $21.2 million, or $0.89 per share, for the quarter ended September 30, 2026, compared to a net loss of $6.6 million, or $1.68 per share, for the quarter ended September 30, 2025.
  • Cash, cash equivalents and investments were $32.3 million as of September 30, 2026, compared to $88.3 million as of December 31, 2025.
  • Net cash used in operations was $18.98 million for the quarter ended September 30, 2026, compared to $4.7 million for the quarter ended September 30, 2025.
  • Research and development expenses were $14.6 million for the quarter ended September 30, 2026, compared to $2.8 million for the quarter ended September 30, 2025.
  • General and administrative expenses were $6.9 million for the quarter ended September 30, 2026, compared to $4.0 million for the quarter ended September 30, 2025.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →